NORTH BRUNSWICK, N.J., Aug. 24, 2023 /PRNewswire/ -- Ascendia Pharmaceuticals®, a leading specialty pharmaceutical contract development and manufacturing organization (CDMO) in North America, proudly announces it has been named to the prestigious 2023 Inc. 5000 list for the fourth consecutive year. Ascendia ranked #1998 in the 2023 list based upon its 280% 3-year revenue growth.
NORTH BRUNSWICK, N.J., June 27, 2023 /PRNewswire/ -- Ascendia Pharmaceuticals CEO Jim Huang, Ph.D. announces Ascendia's patented EmulSol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval from the Food & Drug Administration (FDA). Ascendia, a leading specialty CDMO, developed the formulation in partnership with AcuteBio, LLC.
Enforcement Report - Week of June 2, 2021
Ascendia Pharmaceuticals, a specialty contract development and manufacturing organization (CDMO) dedicated to developing and manufacturing enhanced formulations for pre-clinical, clinical stage drug candidates, and marketed drug products, has received an investment made by Signet Healthcare Partners, a New York-based growth equity firm specializing in healthcare investments. The proceeds will be used to fund Ascendia’s facility expansion to support the growing demand in the sector.
NORTH BRUNSWICK, N.J., Sept. 24, 2020 /PRNewswire/ -- Inc. magazine announces that Ascendia has made the annual Inc. 5000 list, the most prestigious ranking of the nation's fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy's most dynamic segment—its independent small businesses.
Daliresp (Roflumilast) : AstraZeneca vs. Alkem
Takeda Pharmaceuticals v. Alkem Laboratories